Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE fails to recommend pembrolizumab in final draft guidance

europeanpharmaceuticalreviewMarch 17, 2020

Tag: NICE , pembrolizumab , cancer

PharmaSources Customer Service